top of page

Rafarma announces cooperative agreement with the St. Petersburg Academy of Pharmaceutical Chemistry

On February 3, 2014, Rafarma Pharmaceuticals (OTC: RAFA) management met with senior faculty members of the St. Petersburg Academy of Pharmaceutical Chemistry to create a long-term cooperative agreement.

Rafarma will work with and be able to recruit from the finest pharmaceutical specialists graduating in Russia, as well as having access to the Academy?s innovative pharmaceutical research.

The cooperative agreement is borne out of the initiatives outlined in "Pharma 2020", the Russian National Pharmaceutical Strategy. For the Academy, the agreement creates specialized and tailored educational programs allowing undergraduates exposure to Rafarma's most innovative testing protocols at Rafarma?s state-of-the-art facilities under highly-skilled technical supervision.

"Such cooperative agreements with pharmaceutical higher education continue to raise Rafarma?s leadership position in the Russian pharmaceutical industry. We are delighted to have an institution of such extraordinary reputation as a partner", commented Rafarma's CEO David Anderson.


Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.


A center of academic excellence, the St. Petersburg Academy of Pharmaceutical Chemistry was established 90 years ago and is currently the most prestigious higher education facility in Russia. With over 175 faculty members the Academy has more than 3,000 students studying 57 different subjects; producing the most highly-qualified specialists for the Russian pharmaceutical industry. The graduates of the Academy are citizens of more than 40 countries of Europe, Asia, Africa and Latin America. The Academy is the winner of international prize "Profession is Life" in the category "Best medical school", has a Gold Medal "European Quality" in the nomination "100 Best Universities of Russia" (2004, 2005, 2009) and Gold Medal "Top 100 in Russia in Science and Education" (2010).

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate,", "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

SOURCE: Rafarma Pharmaceuticals, Inc.


bottom of page